Sartorius Stedim Biotech S.A.
Sartorius Stedim Biotech S.A. Fundamental Analysis
Sartorius Stedim Biotech S.A. (SDMHF) shows weak financial fundamentals with a PE ratio of 59.26, profit margin of 8.95%, and ROE of 6.60%. The company generates $3.0B in annual revenue with weak year-over-year growth of 0.16%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 34.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze SDMHF's fundamental strength across five key dimensions:
Efficiency Score
WeakSDMHF struggles to generate sufficient returns from assets.
Valuation Score
WeakSDMHF trades at a premium to fair value.
Growth Score
WeakSDMHF faces weak or negative growth trends.
Financial Health Score
ExcellentSDMHF maintains a strong and stable balance sheet.
Profitability Score
WeakSDMHF struggles to sustain strong margins.
Key Financial Metrics
Is SDMHF Expensive or Cheap?
P/E Ratio
SDMHF trades at 59.26 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, SDMHF's PEG of 91.46 indicates potential overvaluation.
Price to Book
The market values Sartorius Stedim Biotech S.A. at 3.85 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 9.27 times EBITDA. This is generally considered low.
How Well Does SDMHF Make Money?
Net Profit Margin
For every $100 in sales, Sartorius Stedim Biotech S.A. keeps $8.95 as profit after all expenses.
Operating Margin
Core operations generate 17.69 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $6.60 in profit for every $100 of shareholder equity.
ROA
Sartorius Stedim Biotech S.A. generates $3.32 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Sartorius Stedim Biotech S.A. produces operating cash flow of $547.70M, showing steady but balanced cash generation.
Free Cash Flow
Sartorius Stedim Biotech S.A. produces free cash flow of $153.95M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $1.58 in free cash annually.
FCF Yield
SDMHF converts 0.98% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
59.26
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
91.46
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.85
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.30
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.67
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.02
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.08
vs 25 benchmark
How SDMHF Stacks Against Its Sector Peers
| Metric | SDMHF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 59.26 | 28.25 | Worse (Expensive) |
| ROE | 6.60% | 780.00% | Weak |
| Net Margin | 8.95% | -20122.00% (disorted) | Weak |
| Debt/Equity | 0.67 | 0.30 | Weak (High Leverage) |
| Current Ratio | 1.02 | 4.66 | Neutral |
| ROA | 3.32% | -14687.00% (disorted) | Weak |
SDMHF outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Sartorius Stedim Biotech S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
83.81%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-28.90%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
150.33%
Industry Style: Defensive, Growth, Innovation
High Growth